The value of gadoxetic acid-enhanced hepatospecific phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver

European journal of Clinical and Medical Oncology

Volumn 2, Issue 4, 2010, Pages

  Filippone, Antonella ^a   Cianci, Roberta ^a   Patriarca, Guido ^a   Sabatino, Federica ^a   Tartaro, Armando ^a   Cotroneo, Antonio Raffaele ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Dysplastic nodule; GD EOB DTPA enhanced MR imaging dynamic MRI; Hepatocellular carcinoma; Liver cirrhosis; Liver specific contrast media; Magnetic resonenceimaging

Indexed keywords

GADOXETIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; FALSE POSITIVE RESULT; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER NODULE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; SENSITIVITY AND SPECIFICITY;

EID: 79956097448     PISSN: 17598958     EISSN: 17598966     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bosch FX, Ribes J, Cleries R, et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9:191-211.
2. Efremidis SC, Hytiroglou P. The multistep process of hepatocarcinogenesis in cirrhosis with imaging correlation. Eur Radiol. 2002;12:753-764.
3. Kudo M. Multi step human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol. 2009;44(Suppl 19):112-118.
4. Ariff B, Lloyd CR, Khan S, et al. Imaging of liver cancer. World J Gastroenterol. 2009;15:1289-1300.
5. Willat JM, Hussain HK, Adusumillis S, et al. Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247:311-330.
6. Zech CJ, Reiser MF, Herrnam KA. Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art. Dig Dis. 2009;27:114-124.
7. Matsui O, Kadoya M, Kameyama T, et al. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology. 1991;178:493-497.
8. Lencioni R, Cioni D, Crocetti L, et al. Magnetic Resonance Imaging of the liver tumors. J Hepatol. 2004;40(1):162-171.
9. Efremidis SC, Hytiroglou P, Matsui O. Enhancement patterns and signal intensity characteristics of small hepatocellular carcinoma in cirrhosis: pathologic basis and diagnostic challenges. Eur Radiol. 2007;17(11):2969-2982.
10. Bartolozzi C, Donati F, Cioni D, et al. MnDPDP enhanced MRI vs dulaphase spiral CT in the detection of hepatocellular carcinoma in cirrhosis. Eur Radiol. 2000;10:1697-1702.
11. Park YN, Yang CP, Fernandez GJ, et al. Neoangiogenesis and sinusoidal ''capillarization'' in dysplastic nodules of the liver. Am J Surg Pathol. 1998;22:656-662.
12. Krinsky GA, Zivin SB, Thorner KM, et al. Low-grade siderotic dysplastic nodules: determination of premalignant lesions on the basis of vasculature phenotype. Acad Radiol. 2002;9:336-341.
13. Kim JI, Lee JM, Choi JY, et al. The value of Gadobenate Dimeglumine enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol. 2008;43:202-210.
14. Motosugi V, Ichikawa T, Tominaga L, et al. Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time? Eur Radiol. 2009;19:2623-2629.
15. Kogita S, Imai Y, Okada M, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol. 2010 Oct;20(10):2405-2413. Epub 2010 May 19.
16. Bruix J, Sherman M, Llovet M et al. EASL Panel of experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35:421-430.
17. Bruix J, Sherman M. Management of hepatocellalar carcinoma. Hepatology. 2005;42:1208-1236.
18. van den Bos IC, Hussain SM, Dwarkasing RS, et al. MR imaging of hepatocellular carcinoma: relationship between lesion size and imaging findings, including signal intensity and dynamic enhancement pattern. J Magn Reson Imaging. 2007;26:1548-1555.
19. Hayashida M, Ito K, Fujita T, et al. Small hepatocellular carcinoma in cirrhosis: differences in contrast enhancement effects between helical CT and MR imaging during multiphasic dynamic imaging. Magn Reson Imaging. 2008;26(1):65-71.
20. Kim YK, Lee YH, Kim CS, et al. Added diagnostic value of T2-weighted MR imaging to gadolinium-enhanced three-dimensional dynamic MR imaging for the detection of small hepatocellular carcinomas. Eur J Radiol. 2008;67(2):304-310.
21. Saito K, Kotake F, Ito N, et al. Gd-EOB-DTPA-enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci. 2003;4:1-9.
22. Borzio M, Fargion S, Borzio F, et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol. 2003;39:208-214.
23. Ahn SS, Kim MS, Lim JS, et al. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology. 2010;255(2):59-466.
24. Grazioli L, Morana G, Caudana R, et al. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. Invest Radiol. 2000;35(1):25-34.
25. Narita M, Hatana E, Arizona S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol. 2009;44:793-798.
26. Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut. 2010;59:638-644.